Timmerman Report
Online/Digital
Timmerman Report is an independently-owned subscription publication that provides timely, in-depth biotech news and analysis. It’s for anyone who seeks to understand new drug development, diagnostics, genomics, and other technologies that are changing medicine.
I’m looking for the true innovations, the emerging trends, the market forces, and the characters at work. Because I’ve been covering the industry for more than a decade—through two busts and one and a half booms—I bring context to stories that few can match. Readers should expect big picture perspective, and a steady drumbeat of news, features, and original commentary.
This type of in-depth reporting will help prepare you for your next big meeting, find a partner, jump on an investment opportunity, hire an up-and-comer, get to know the people you work with, or land a job.
My goal is to write accessibly for all of you: in a way that specialized readers can appreciate and lay readers can understand. It’s the sort of clear, probing and contextual journalism that never goes out of style. Source
Actions
Media Outlet details
| Scope | National, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesHarell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery
The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something useful – predicting protein structures in this case. Those scientists never got a nickel. This is just one of many examples in which AI model builders hoovered up public data for free and now are making their fortunes.
The Narrative Machine: What AI Really Adds to Personal Health Data
For years, the Quantified Self movement had a stubborn problem: our devices became increasingly good at generating data but remained remarkably poor at telling us what any of it meant. Generative AI now dangles a tantalizing possibility: that it can tease genuinely useful personal insights from all those measurements and hand them back to us in a form we can immediately understand and readily apply.
The Other Side of Bayes: Rethinking False Positives in Health Screening
Imagine screening 10,000 apparently healthy people for a disease that affects one person in a thousand. Let’s further assume the test is fairly good: 99% sensitive and 99% specific. (In case it’s been a while, this means the test detects 99% of true cases and correctly exonerates 99% of people without disease.) Ten of those 10,000 people will actually have the disease –- that’s just the prevalence of the condition in the population. The test will identify essentially all of them.
AI in Drug R&D: At Last, the End of the Beginning
With the emergence of AI as an increasingly dominant force in industry (and society), much of the early discussion around AI in biopharma has tended to treat it largely as an abstraction. Advocates and investors insist AI is a transformative superhuman technology poised to domesticate R&D, while cynics, including many grizzled drug hunters, tend to assume it’s just the latest in a long series of overhyped bright and shiny objects, destined first to distract, then to disappoint.
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run
Jason Coloma is today’s guest on The Long Run. Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can make people sick, or protect them from falling ill.
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run
Lyn Baranowski is today’s guest on The Long Run. Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Lyn Baranowski, CEO, Avalyn Pharma Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more effectively delivered where they need to go, deep in the lungs.